UNSPSC 51162035: Phenobarbital/potassium iodide/sodium bicarbonate/theobromine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162035 Phenobarbital/potassium iodide/sodium bicarbonate/theobromine is a Commodity code that in recent state and local practice spans a much broader range of pharmaceutical procurement than its narrow chemical formulation suggests — state and local buyers are using this code to solicit naloxone, pharmacy services, generic multi-source pharmaceuticals, OTC products, and direct-to-manufacturer prescription programs. The issuing bodies include county health departments, county employee health plans, state health and human services agencies, and multistate cooperative purchasing alliances. Scope varies from emergency-response medications (naloxone kits for community health and drug deactivation systems) to ongoing pharmacy operations supporting employee and retiree health insurance plans, bulk generic and OTC pharmaceutical supply agreements across multiple government jurisdictions, and exploratory procurement around value-based or outcomes-based pharmacy models that bypass traditional pharmacy benefit managers.

Recent activity spans Florida, Georgia, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. Hall County, Georgia released RFQ/P #47-010 (due June 4, 2026) for on-site pharmacy services at its Family Health Center Clinic serving approximately 3,005 eligible individuals across multiple health insurance plans, with an 80/20 technical-to-cost scoring structure and one-year initial term plus four optional renewals. The Texas Health and Human Services Commission issued an RFI (HHS0017013, April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional PBM and GPO channels. MMCAP (Minnesota Department of Administration), administering a multistate cooperative, released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026, and performance-penalty provisions ranging from $200 to $1,500 per violation.